Table 8.
Score changes in nasal and ocular symptoms as per the JRQLQ No.1 from 0 to 16 weeks in the sub-groups with a low friendliness score in Profile of Mood States 2 questionnaire (POMS 2).
| Items | Group | n | 4 Week | 8 Week | 12 Week | 16 Week |
|---|---|---|---|---|---|---|
| Rhinorrhea | LH2171 | 44 | 0.0 ± 0.8 | 0.0 ± 0.7 | 0.1 ± 0.8 | 0.1 ± 0.9 |
| Placebo | 44 | 0.1 ± 0.8 | 0.2 ± 0.7 | 0.0 ± 0.8 | 0.0 ± 0.7 | |
| Sneezing | LH2171 | 44 | 0.0 ± 0.5 | 0.1 ± 0.5 | 0.0 ± 0.6 | −0.1 ± 0.7 |
| Placebo | 44 | 0.0 ± 0.5 | 0.1 ± 0.6 | 0.0 ± 0.5 | −0.1 ± 0.7 | |
| Nasal obstruction | LH2171 | 44 | 0.0 ± 0.4 | 0.1 ± 0.6 | 0.1 ± 0.6 | 0.0 ± 0.9 |
| Placebo | 44 | −0.1 ± 0.6 | −0.1 ± 0.7 | −0.2 ± 0.7 | 0.0 ± 0.6 | |
| Nose itching | LH2171 | 44 | −0.1 ± 0.6 | 0.1 ± 0.6 | −0.1 ± 0.7 | −0.3 ± 0.6 * |
| Placebo | 44 | 0.0 ± 0.6 | 0.0 ± 0.8 | 0.0 ± 0.6 | −0.2 ± 0.6 * | |
| Eye itching | LH2171 | 44 | −0.2 ± 0.6 * | −0.2 ± 0.9 * | −0.3 ± 0.8 * | −0.5 ± 0.8 ***# |
| Placebo | 44 | −0.1 ± 0.6 | 0.0 ± 0.8 | −0.2 ± 0.8 | −0.1 ± 0.9 | |
| Tearing | LH2171 | 44 | 0.0 ± 0.5 | 0.0 ± 0.5 | 0.0 ± 0.6 | 0.0 ± 0.7 |
| Placebo | 44 | −0.1 ± 0.8 | −0.1 ± 0.6 | −0.1 ± 0.8 | −0.2 ± 0.8 | |
| Nasa and ocular symptoms score (total score) | LH2171 | 44 | −0.2 ± 2.2 | 0.0 ± 2.5 | −0.3 ± 2.6 | −0.7 ± 3.2 |
| Placebo | 44 | −0.2 ± 2.4 | 0.2 ± 3.0 | −0.6 ± 2.8 | −0.6 ± 2.9 | |
| Nasal symptoms (total score) | LH2171 | 44 | 0.0 ± 1.6 | 0.2 ± 1.6 | 0.1 ± 2.0 | −0.3 ± 2.3 |
| Placebo | 44 | 0.0 ± 1.5 | 0.2 ± 2.1 | −0.2 ± 1.7 | −0.3 ± 1.9 | |
| Ocular symptoms (total score) | LH2171 | 44 | −0.2 ± 0.9 | −0.2 ± 1.3 | −0.3 ± 1.1 | −0.5 ± 1.2 * |
| Placebo | 44 | −0.2 ± 1.2 | −0.1 ± 1.3 | −0.3 ± 1.5 | −0.3 ± 1.5 |
Mean ± standard deviation. # p < 0.05 compared with the placebo group as per the Mann-Whitney U test, * p < 0.05, *** p < 0.001 compared with the 0-week time-point, as per the Wilcoxon signed-rank test.